Cardiomyopathy is associated with cardiac Na + channel downregulation that may contribute to arrhythmias. Previously, we have shown that elevated intracellular NADH causes a decrease in cardiac Na + current (I Na ) signaled by an increase in mitochondrial reactive oxygen species (ROS). In this study, we tested whether the NADH-mitochondria ROS pathway was involved in the reduction of I Na in a nonischemic cardiomyopathic model and correlated the findings with myopathic human hearts.
Introduction
Despite extensive research and novel treatments, conditions associated with deranged cardiac metabolism, such as heart failure or ischemia, are accompanied still by a substantial risk of arrhythmic sudden death [1] . While implanted cardiac defibrillators have decreased sudden death risk, they can cause physical and psychological complications. They are also expensive, and do not address the underlying pathology that leads to arrhythmic risk [2, 3] . A more complete molecular understanding of the basis for the increased arrhythmic risk is likely to lead to new therapies that will be more effective and less invasive.
Cardiac injury from many causes is associated with altered metabolism and downregulation of the cardiac Na + channel (Na v 1.5) [4] [5] [6] [7] . Recently, we reported that an elevation of intracellular reduced nicotinamide adenine dinucleotide (NADH) can downregulate Na + current (I Na ) acutely and to a degree that is large enough to be clinically significant [8] . The signaling cascade involves a protein kinase C (PKC)-mediated increase in mitochondrial reactive oxygen species (ROS) production [9, 10] . NADH is known to oscillate with myocardial ischemia, and mitochondrial injury is associated with increased NADH and ROS levels [11, 12] . These changes could contribute to reduced I Na , conduction block, and arrhythmic risk known to exist with reduced cardiac contractility. The NADH effect on ROS production and I Na can be antagonized by PKA activation mediated by NAD + , by superoxide dismutase, or by mitoTEMPO, a specific scavenger of mitochondrial ROS [9, 10] . To evaluate the clinical relevance of this signaling pathway, we tested whether NADH and mitochondrial ROS were elevated in nonischemic cardiomyopathy and whether these changes resulted in a reduction in I Na . We also investigated whether NAD + , mitoTEMPO, PKC inhibitors (a PKC pan inhibitor chelerythrine and δV1-1, a specific inhibitor for PKCδ), or a PKA activator (forskolin) could counteract the effects of NADH on mitochondrial ROS and cardiac I Na . We evaluated the role of the β-adrenergic receptor (β-AR), CD38, and the purinergic receptor [13] [14] [15] [16] , to determine how extracellular NAD + , which is membrane impermeable, affected I Na . To show relevance of the findings, the effect of NAD + on conduction velocity (CV) in human failing hearts was evaluated.
Materials and Methods

Model generation and isolation of mice ventricular myocytes
Nonischemic cardiomyopathy was induced in C57BL/6 mice by six weeks of hypertension evoked after unilateral nephrectomy, deoxycorticosterone acetate (DOCA) pellet implantation (0.7 mg/day, Innovative Research of America, Sarasota, FL), and 1% salt water substitution [17] . Sham operated mice were used as controls. Ketamine (100 mg/kg) and xylazine (10 mg/kg) were administrated by intraperitoneal pre-operation and buprenorphine (0.1 mg/kg) was injected subcutaneously post-operation and at 12-hour interval as needed. For each experiment, three to eight mice were used.
Ventricular myocytes were isolated as described before [17, 18] . Briefly, hearts were excised from anesthetized mice, perfused with perfusion buffer (in mM: NaCl 113, KCl 4.7, Na 2 HPO 4 0.6, KH 2 PO 4 0.6, MgSO 4 1.2, Phenol Red 0.032, NaHCO 3 12, KHCO 3 10, HEPES 10, Taurine 30, 2-3-butanedione monoxime 10) and digested with collagenase II (Worthington Biochemical Co. Lakewood, NJ). Cardiomyocytes were washed with control buffers (in mM: NaCl 133.5, KCl 4, Na 2 HPO 4 1.2, HEPES 10, MgSO 4 1.2) with serially increasing Ca 2+ concentrations (0.2, 0.5, and 1 mM). Then, myocytes were incubated in MEM medium (modified Eagle's medium with 1% insulin-transferrin-selenium, 0.1% bovine serum albumin, 1% L-glutamine, and 1% penicillin/streptomycin) in a 95% O 2 /5% CO 2 incubator at 37 ºC for 2 hours prior to being used for patch clamp recording and ROS level measurements.
Documentation of cardiomyopathy
Blood pressure and heart rate were measured on acclimated conscious mice six weeks after surgery using tail-cuff plethysmography (Columbus Instruments, Columbus, Ohio).
Transthoracic echocardiography was performed using the Vevo 770 system equipped with a RMV-707B transducer (VisualSonics, Toronto, Canada). Mice were anesthetized with 1% isoflurane in oxygen and were closely monitored during the procedure. Images were obtained from the parasternal long axis view and parasternal short axis view at the midpapillary level. Wall thickness, chamber size, fractional shortening (%FS), and ejection fraction (%EF) were evaluated by two-dimensional and M-mode echocardiography. Measurements were averaged from three consecutive beats.
Whole cell and cytosolic NADH and NAD
+ levels We measured both whole cell and cytosolic NADH and NAD + levels of mouse heart tissue from sham and DOCA mice. We also tested whether injection of NAD + to sham and DOCA mice (100 mg/kg, twice at 24 h and 1 h before heart harvest) affected the cytosolic NADH and NAD + levels. Four animals were used for each group. The cytosol of cardiomyocytes was isolated from mitochondria with the Mitochondria Isolation Kit for Tissue (Pierce Biotechnology, Rockford, IL) by following the manufacturer's protocol. The EnzyChrom TM NAD + /NADH Assay Kit (BioAssay Systems, Hayward, CA) was used to measure NADH and NAD + levels from whole cells and cytosol according to the manufacturer's instructions. The absorption intensity difference of the reduced product color, measured at 565 nm at time zero and 15 min later, was used to calculate NADH and NAD + levels.
2.4. Cellular electrophysiology Na + currents of ventricular myocytes were measured using the whole-cell patch clamp technique in voltage-clamp mode at room temperature [9, 10] . To measure Na + currents, pipettes (1-2 MΩ) were filled with a pipette solution containing (in mM): CsCl 80, cesium aspartate 80, EGTA 11, MgCl 2 1, CaCl 2 1, HEPES 10, and Na 2 ATP 5 (adjusted to pH 7.4 with CsOH). The bath solution consisted of (in mM): NaCl 15, CsCl 5, CaCl 2 1, MgCl 2 1, tetramethylammonium Cl 20, N-methyl-D-glucamine 100, 4-aminopyride 3, MnCl 2 2, HEPES 10 and glucose 10 (adjusted to pH 7.4 with CsOH). To measure current, a stepped voltage protocol from -100 to +60 mV with a holding potential of -100 mV was applied to establish the presence of Na v 1.5. Peak currents obtained during steps to -20 mV were used for comparison in determining the relative reduction of I Na . To minimize time-dependent drift in gating parameters, all protocols were initiated 2-5 min after whole-cell configuration was obtained. The currents were normalized with cell capacitance.
To measure the resting membrane potential, perforated current-clamp was performed on isolated myocytes from sham and DOCA mice [19] . The pipette solution contained (in mM): potassium gluconate 120, KCl 20, NaCl 5, HEPES 5, MgATP 5, and β-escin 0.03 (adjusted to pH 7.2 with KOH). The bath solution consisted of (in mM): NaCl 140, KCl 5.4, MgCl 2 1, HEPES 5, CaCl 2 1.8, and glucose 5.5 (adjusted to pH 7.4 with NaOH). Pipette resistance were 3-5 MΩ.
Measurement of mitochondrial ROS
To measure mitochondrial ROS, the fluorescent probe MitoSOX TM Red (Invitrogen) was used according to the manufacturer's protocol. Briefly, ten groups of isolated cardiomyocytes were studied: sham mouse myocytes, DOCA mouse myocytes, and myocytes from sham or DOCA mice treated with 500 µM NAD + , 10 µM mitoTEMPO, 2 µM δV1-1, or 5 µM forskolin for 10-min at 37 ºC. Cells were then washed once with MEM and incubated with 5 µM MitoSOX TM Red and 100 nM MitoTracker Green (Invitrogen) for 10 min at 37 ºC, followed by washing three times with MEM medium. Images were taken on a Zeiss LSM710 confocal microscope (Carl Zeiss GmbH, Germany) using an argon laser excitation (514 nm) with emission collection through a 560 nm long pass filter. Analysis of Na + channels present at the cell surface was performed on freshly isolated cardiomyocytes of sham and DOCA mice as previously described with the Pierce ® Cell Surface Protein Isolation Kit (Pierce Biotechnology, Rockford, IL) [20] . For detection of Na v 1.5, the primary antibody (rabbit anti-SCN5A, Alomone Labs, Jerusalem, Israel) was diluted 1:200. Horseradish peroxidaseconjugated goat anti-rabbit IgG secondary antibody (Cell Signaling Technology, Danvers, MA) was diluted 1:5000. Actin (Santa Cruz Biotechnology, CA) was used as a loading control. Six animals were used for each group.
SCN5A RNA abundance
Total RNA was isolated (RNeasy Minikit -Qiagen, Valencia, CA) from snap frozen ventricular tissue samples taken from sham and DOCA mice (n=3 per group). Equal quantities of total RNA from all samples were used to generate cDNA using the High Capacity cDNA synthesis kit (Applied Biosystems, Carlsbad, CA), and quantitative PCR was performed using Fast SYBR green chemistry (Applied Biosystems, Carlsbad, CA) on an ABI 7500 platform. Primers were designed against mouse SCN5A (SCN5A_F TTGCTCCTTCTCTCATGGTTG and SCN5A_R CATGGAGATGCTCAAGAAGGA) and Hypoxanthine phosphoribosyltransferase (HPRT) (HPRT_F AGGCCAGACTTTGTTGGATTT and HPRT_R GGCTTTGTATTTGGCTTTTCC) using Primer3 plus software (http://www.bioinformatics.nl/cgi-bin/primer3plus) and synthesized by MWG (Huntsville, AL). HPRT acted as the housekeeping gene by which to normalize SCN5A cDNA. The 2 -∆∆Ct method was used for relative quantification between groups. A t-test was used for test for statistical comparison between the two groups.
Conduction velocity measurement with human failing heart tissue
Failing human hearts (n=3) of different cardiomyopathies (supplemental data) were provided by Barnes-Jewish Hospital (Washington University in Saint Louis, Mo) and non-failing donor hearts (n=2) were provided by Mid-America Transplant Services (Saint Louis, MO) for comparative purposes. Optical mapping experiments of human hearts were done as previously described [21, 22] . Briefly, left ventricular (LV) wedge preparations were isolated from the posterior-lateral LV free wall and perfused through the left marginal artery with Tyrode's solution. Tissue was stained with di-4-ANNEPS (15 μM; Molecular Probes, Eugene, Oregon) for recording optical action potentials and was immobilized by addition of blebbistatin (10-20 μM; Tocris Bioscience, Ellisville, MO) to reduce motion artifact.
LV wedge preparations were paced at the sub-endocardium at twice the diastolic pacing threshold with a 5-ms pulse width. A restitution pacing protocol was conducted, in which pacing started at 2000 ms and decreased until the ventricular functional refractory period was reached. Following control pacing, NAD + (500 μM) was bolus-injected into a drug port. Tissue was allowed to stabilize for 25-30 minutes and then a second restitution pacing protocol was performed. Data was analyzed using custom MATLAB software [23] . All optical data were filtered using a 3×3 pixel spatial filter and a 0-100 Hz finite impulse response filter. Activation times were defined as the maximum first derivative of the fluorescent signal and CV was calculated as described by Bayly et al. [24] . The magnitude of CV was determined to be the median conduction calculated in the region of interest (Fig. 6D middle) . The Student's paired t-test was used to determine the level of statistical significance (P<0.05).
Statistical evaluations
Data are shown as the mean ± SEM. Aside from above, determinations of statistical significance were performed with ANOVA with the Bonferroni correction for comparisons of multiple means. A value of P<0.05 was considered statistically significant.
Results
At six weeks after surgery, DOCA mice had developed hypertension and systolic heart dysfunction confirmed by tail-cuff blood pressure measurements and echocardiography. As shown in Table 1 , compared to the sham mice, DOCA mice showed higher artery blood pressure, enlarged left ventricular chamber (105 ± 4 vs. 88 ± 6 µL of sham, P<0.05), and reduced ejection fraction (37±2% vs. 49±4% of sham, P<0.05).
Elevated NADH level in cardiomyopathic heart tissue
We measured whole cell and cytosolic NADH and NAD + levels of sham and DOCA mice hearts, before and after treatment with NAD + . Fig. 1 shows the ratios of whole cell and cytosolic NADH and NAD + levels, and NADH/NAD + . The whole cell and cytosolic NAD + levels of the sham and DOCA groups were similar. On the other hand, NADH was increased 279±70% for whole cell and 123±2% for cytosol in DOCA mice (P<0.01 vs. sham for both). Consistent with the hypothesis that cytosolic NADH changes mediate the effects on I Na , DOCA mice injected with NAD + showed a similar cytosolic NADH level as the sham group (110±8% of sham, P>0.05). Injection of NAD + had no influence on cytosolic NADH and NAD + levels in sham mice. The cytosolic NADH/NAD + ratios of all groups were similar, although the whole cell NADH/NAD + ratio of DOCA group was increased 220±69%, compared to the sham group. According to our previous work, an increase in intracellular NADH level could lead to significant decrease of I Na [9] . Therefore, we measured the I Na of isolated myocytes of sham and DOCA mice.
3.2. Decreased I Na in cardiomyopathic ventricular cardiomyocytes Fig. 2A shows representative traces of I Na measured from isolated sham and DOCA ventricular myocytes. The I Na of DOCA myocytes was decreased significantly. Fig. 2B presents the averaged peak currents measured at -20 mV with a holding potential of -100 mV, I Na of the cardiomyopathy group being 60±10% of the sham (P<0.01). While we did not measure serum Na + changes induced by DOCA treatment, the anticipated increase is not likely to compensate for the reduced current observed in the patch clamp experiments nor is it likely that the reduction in current observed is in compensation for this anticipated small increase in driving force for Na + entry. The decrease in I Na was not related to changes in transcription, because quantification of SCN5A mRNA revealed no significant difference in transcript levels with the sham and DOCA heart tissue (P=0.95). To investigate Na v 1.5 membrane expression, we labeled channels present on the membrane surface with biotinylation. Western blot analysis for biotinylated Na + channels showed no significant difference between sham and DOCA mice as in Fig 3: 1.63 ± 0.21 vs. 1.39 ± 0.19, n=6 for each group, P=0.42. The resting membrane potential of DOCA mice myocytes (-78.3 ± 5.0 mV) was not altered compared to the sham group (-75.5 ± 0.8 mV, P>0.05).
Restoring I Na
In our previous studies on ventricular cells from normal hearts, NAD + , mitoTEMPO, chelerythrine and forskolin reversed a NADH-induced decrease of I Na [9, 10] . In this work, intracellular application of NAD + , mitoTEMPO, chelerythrine, or forskolin (500, 10, 50, or 5 μM, respectively) to isolated myocytes of cardiomyopathic mice restored I Na from 60±10% to 97±7%, 93±8%, 112±86%, 109±6% of sham at -20 mV, respectively (Fig 4A and 4C, P>0.05 ). As shown in Fig. 4A and 4B, there were minor shifts of V 1/2 values of steady state activation and inactivation, but they were not enough to affect the evaluation of the peak currents. Treatment of sham myocytes with these compounds had no influence on I Na (data not shown).
Treating animals with NAD + and mitoTEMPO had similar effects as applying these compounds to isolated myocytes. We injected the animals twice with NAD + (100 mg/kg) or mitoTEMPO (0.7 mg/kg), at 24 hours and 1 hour before the myocyte isolation. As shown in Fig 4D and 4F , NAD + or mitoTEMPO completely restored the decreased I Na seen in myopathic myocytes (115±9% and 119±9% of sham injected with NAD + or mitoTEMPO, respectively, at -20 mV, P>0.05). As shown in Fig. 4D and 4E, there were also minor shifts of V 1/2 values of steady state activation and inactivation that were not enough to affect the evaluation of the peak currents. There were subtle differences in the response of Na + channel kinetics to treatment in vivo and in vitro. The origin and the significance of these differences are unknown. Doses for the treatment drugs were based on demonstration of maximal I Na recovery in vitro. The lack of difference between in vitro and in vivo treatment effects suggests the doses used in vivo were also sufficient to induce a maximal effect.
Mitochondrial ROS are increased in myopathic ventricular myocytes
Previously, we have shown that elevated NADH increases mitochondrial ROS production, causing a reduction of Na + current [9, 10] . To test if this mechanism of the I Na reduction was similar in a clinically relevant model, MitoSOX TM Red was used to demonstrate mitochondrial ROS production in myopathic ventricular myocytes of DOCA mice. As shown in Fig. 5A , the mitochondrial ROS level of myopathic myocytes increased 2.9 ± 0.3-fold (P<0.01 vs. sham). This is similar to a four-fold increase of superoxide production observed in the aortas of DOCA mice [25] .
Treatment of myocytes with NAD + , mitoTEMPO, δV1-1, or forskolin (500, 10, 2, or 5 μM, respectively) extracellularly led to decreases of ROS in myopathic mouse myocytes to levels similar to the sham group (1.4 ± 0.1, 1.1 ± 0.1, 0.9 ± 0.1, or 0.8 ± 0.1-fold of sham, respectively, P>0.05). Here, we used the specific inhibitor of PKCδ, δV1-1, instead of chelerythrine, because chelerythrine's fluorescence affected the evaluation with MitoSOX TM Red. Fig. 5C shows representative confocal images of these measurements. Treatment of sham myocytes with these compounds had no effect on mitochondrial ROS production (data not shown). For the animal treated groups, we used flow cytometry to test the MitoSOX TM Red fluorescence. This method measured ~ 10,000 myocytes for each group to produce more reliable measure of net mitochondrial ROS. Similar results to those with confocal microscopy were obtained with sham, DOCA and DOCA mice injected with NAD + or mitoTEMPO (100 or 0.7 mg/kg, respectively; Fig 5B) . The mean fluorescent intensity of the myopathic DOCA group was increased by 1.7 ± 0.1-fold when compared to sham (P<0.05). NAD + and mitoTEMPO decreased the mitochondrial ROS overproduction in myopathic mouse myocytes to 1.1 ± 0.2-and 1.0 ± 0.1-fold of sham, respectively (P>0.05).
Extracellular NAD
+ signals mainly through CD38 We evaluated the role of the β-adrenergic receptor (β-AR), CD38, and the purinergic receptor [13] [14] [15] [16] , to determine how extracellular NAD + , which is membrane impermeable, affected I Na . NADH applied in the pipette solution induced a 62±4% reduction of I Na at -20 mV. NAD + recovered the decreased I Na to 93±3% of control. Specific inhibitors for CD38 (pelargonidin at 160 μM) [26] , β-AR (Nadolol at 20 μM) [27, 28] , and purinergic receptors (suramin at 100 μM) [29, 30] were applied respectively to the extracellular solution for 15 min (pelargonidin or Nadolol) or 1 hour (suramin) before addition of NAD + . With pelargonidin, nadolol, and suramin, the I Na upon application of NAD + returned to 63±5% (P<0.01 vs. control), 80±5% (P<0.05 vs control) and 102±7% (P>0.05 vs. control) of control, respectively. The inhibitors did not affect the cardiac I Na when applied separately (data not shown). Therefore, we conclude that mainly CD38 mediates the NAD + effect to recover I Na . The β-AR might play a minor role in the NAD + effect, while the purinergic receptors do not appear to contribute to this signaling pathway.
3.6 NAD + improved the conduction velocity of human failing hearts We tested the clinical relevance of the DOCA mouse model findings in isolated human heart tissue. CV from non-failing and failing hearts were similar to what has been previously reported [31] . Failing hearts showed a reduction in CV that improved with NAD + . For both failing (n=3) and non-failing (n=2) human hearts, CV was calculated both before and after administration of NAD + at several pacing cycle lengths (2000, 1000, 800, 600 ms). Fig. 6A shows a representative LV wedge preparation with key features highlighted. The dotted white line indicates the field of view of activation and CV maps (Fig. 6C  and 6D left) , where the CV was calculated within the teal rectangle. Blue and green circles in Figure 6A specify the location of representative optical action potentials seen in Fig. 6B . The activation map in Fig.  6C depicts the spread of electrical propagation from the location of the pacing electrode near the subendocardium (blue) to the epicardial surface (red).
In Fig. 6D CV vectors (red arrows) are displayed on top of an activation map in gray scale. The center panel magnifies the area (teal box) where the magnitude of CV was determined at all cycle lengths (2000, 1000, 800, 600 ms) for individual wedge preparations. The mean values of CV of failing hearts and control hearts before and after administration of NAD + are listed in Table 2 . After addition of NAD + , the CV of failing heart increased at all cycle lengths and was significantly different at three cycle lengths (2000 ms: P=0.02, 800 ms: P=0.0006, and 600 ms: P=0.003).
Discussion
Voltage-gated Na + channels are responsible for generating the main current for excitation propagation in the membrane of most excitable cells, such as cardiomyocytes and neurons [32, 33] . Cardiac Na + channel changes have been implicated in the increased risk of sudden death in heart failure [34] [35] [36] . In our previous studies on the mechanism by which mutations in glycerol-3-phosphate dehydrogenase 1 like (GPD1L) protein cause reduced I Na and Brugada Syndrome, we have shown that increased cytosolic NADH can downregulate the cardiac Na + channel through PKC activation and mitochondrial ROS overproduction [9, 10] . Here, we demonstrated that the metabolic derangements occurring in cardiomyopathy resulted in reductions in I Na by a similar mechanism. Hypertensive DOCA mice presented enlarged left ventricular chamber and reduced ejection fraction associated with elevated cytosolic NADH level, increased mitochondrial ROS, and reduced I Na . The reduction in I Na was on the order of magnitude seen in Brugada Syndrome. These results reveal links between mitochondrial dysfunction with ROS overproduction, downregulation of cardiac Na v 1.5, and nonischemic cardiomyopathy. The heart tissue of DOCA mice showed no change in SCN5A mRNA abundance or Na v 1.5 protein membrane expression. The reason for decreased I Na is, therefore, not a decrease of Na v 1.5 channel number, but decreases of the probability of channel opening or of the single channel conductance. Surtuins are pyridine nucleotide-dependent histone deacetylases or mono-ribosyltransferases. Given the time scale of the changes in I Na in response to NADH, it is unlikely that a sirtuin-dependent transcriptional change is responsible for the effects observed. Nevertheless, a direct effect of surtuins on the channel cannot be excluded. The increase in cardiac mitochondrial ROS is consistent with other studies showing that DOCA-salt treatment increases ROS production in the aorta of DOCA hypertension mice [17, 25] and rats [37, 38] .
The improved CV of human failing heart by administration of NAD + was consistent with the changes in I Na seen in the DOCA mouse model based on the cable equation, where the CV is proportional to I Na 1/8 . The ratio of CV of the failing hearts versus NAD + -treated failing hearts is 1.05 -1.08 at pacing cycle lengths of 600-2000 ms. This is in range of improvement in CV calculated for the changes in I Na observed in the DOCA mouse myocytes with NAD + treatment (i.e. 1.08). Despite the consistency with the mouse model and the likely salutary nature of improving conduction, we cannot rule out that NAD + had other effects that improved CV aside from increasing I Na .
In the study of the GPD1L A280V mutant, NAD + and mitoTEMPO were able to reverse the phenotype and reduce spontaneously induced arrhythmias in a mouse model of Brugada Syndrome [9] . In this work, we found that these compounds had analogous effects to raise I Na in the nonischemic cardiomyopathy DOCA model. Treating either myocytes directly or the animal, NAD + and mitoTEMPO were able to reduce mitochondrial ROS overproduction and rectify the decreased I Na . This suggests that while there may be other sources of oxidative stress in this cardiomyopathy model, mitochondrial ROS are most important for the reduction in I Na . Interestingly, mitoTEMPO has also been tested in DOCA mice that show hypertension and resulted in reduced blood pressure [39] . NAD + , in a redox couple with NADH, has emerged as a putative metabolic regulator of transcription, longevity and several age-associated diseases, including diabetes, cancer and neurodegenerative diseases. [40] In our previous studies and this work, we have shown that extracellular NAD + increases cardiac Na v 1.5 currents and reduces antiarrhythmic risk in SCN5A +/-hearts, a condition mimicking BrS. [9, 10] Nevertheless, NAD + is impermeable to cell membrane. Extracellular NAD + effects on intracellular signaling have been observed, and there are at least three candidates that may transmit the NAD + signaling from the plasma to the cytosol. They are the β-AR, CD38, and the purinergic receptor [13] [14] [15] [16] . We identified CD38 as the main agent to transduce extracellular NAD + signaling. The ectoenzyme CD38 is a plasma membrane glycoprotein and has been reported to be a NAD + and cyclic ADP-ribose (cADPR) transporter [16, 41, 42] . In addition, it catalyses intracellular cADPR synthesis from NAD + . In our recent unpublished work, we have also found that an antagonist of cADPR, 8-Br-cADPR, impaired the effects of NAD + and forskolin on recovering I Na in HEK cells stably expressing the human cardiac Na v 1.5. These results are consistent with CD38 mediating the NAD + effect. We examined the involvement of PKA and PKC in the reduction of I Na and overproduction of mitochondrial ROS in DOCA mouse myocytes with forskolin, chelerythrine, and δV1-1. They enhanced I Na and blunted the elevated mitochondrial ROS level of DOCA mouse myocytes. This indicates that, similar to the mechanism we have found in the mutant A280V GDP1L modulation of the cardiac Na v 1.5 [9, 10] , PKC activation participates in the signaling pathway decreasing the I Na in DOCA mice myocytes, and that PKA activation can be used to upregulate cardiomyocyte Na v 1.5 of DOCA mice by inhibiting mitochondrial ROS overproduction. In a study of the vertebrate brain type IIA Na + channel expressed in Xenopus oocytes on single channel level, the open time constant decreased from 0.26 ± 0.05 ms to 0.17 ± 0.03 ms with treatment of 5 nM phorbol 12-myristate 13-acetate (PMA, a PKC activator) at -50 mV [43] . Treatment of PMA also led to a reduced peak Na + current, reduced channel open probability, and prolonged time constants for channel activation. A reduction in I Na secondary to changes in channel gating is consistent with our observations that Na v 1.5 mRNA and membrane protein were unchanged with cardiomyopathy or treatment. In data not shown, a specific inhibitor for calcium/calmodulin-dependent protein kinase II (CaMKII), autocamtide-2 related inhibitory peptide (AIP) at 500 nM, could not block the NADH effect on reducing I Na . Therefore, it would seem unlikely that CaMKII plays a significant role in the observed reduction in I Na during nonischemic cardiomyopathy.
Mitochondria comprise ~30-40% of the myocyte volume, generate >90% of the ATP [44, 45] , and play a key role in many cellular functions including energy production, ion homeostasis, and cell signaling of cardiomyocytes. Mitochondria are one of the major sources of ROS in heart disease [46] . It is not surprising to find that mitochondrial dysfunction plays a critical role in nonischemic cardiomyopathy. Mitochondrial dysfunction can result in overproduction of ROS, acute energy failure, and cell death [47] . For example, a study of canine heart failure showed a decrease in the enzymatic activity of the complex I of the mitochondrial electron transport chain in heart failure, which caused the functional uncoupling of the respiratory chain and ROS overproduction [48] . In ischemia/reperfusion injury, the complex I serves as the source of ROS [49] . Mitochondrial injury occurring in ischemia is associated with increased NADH and ROS levels [11, 12] .
It is unclear whether ROS participates directly in channel regulation or a second messenger pathway. The most vulnerable target of the posttranslational redox modifications to proteins is protein cysteine thiols, the oxidation of which may result in reversible molecular disulfide formation or other thiol modifications such as nitrosylation and glutathionylation [50] [51] [52] [53] . In this study of the nonischemic cardiomyopathy model of 6-week DOCA mice, we observed a ~3-fold of mitochondrial ROS overproduction, which participated in the downregulation of cardiac Na v 1.5 function in an unknown mechanism. The specific mitochondrial ROS scavenger, mitoTEMPO curbed the mitochondrial ROS formation and reinstated I Na to the level of sham mice. PKC inhibitors, chelerythrine and δV1-1, were able to diminish the overproduction of mitochondrial ROS and restore the decreased I Na of DOCA mouse myocytes, indicating that mitochondrial ROS generation is regulated by PKC in this cardiomyopathy heart model. NAD + and forskolin showed similar regulations on the mitochondrial ROS and I Na levels of DOCA mouse myocytes as PKC inhibitors. On the other hand, both PKC and PKA-mediated phosphorylation has been shown to regulate the channel directly [54, 55] . It is possible that these kinases are both up and downstream of mitochondrial ROS production or that ROS-dependent modifications and phosphorylation interact at the channel to modulate current. Further experiments will be needed to differentiate these possibilities.
It is well recognized that increasing severity of myopathy parallels sudden death risk [56] and reduced I Na increases arrhythmic risk [57] . These studies suggest that myopathy is linked directly to reduced I Na and describe a mechanism whereby myopathy leads to metabolic derangements and increased mitochondrial ROS production causing the reduced I Na . This work suggests a reduction in mitochondrial ROS in cardiomyopathy will reverse the reduced I Na and possibly some of the arrhythmic risk by improving conduction velocity.
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